Evidence map›Paper›PMID 40597820›Full record

ReviewBMC nephrology2025

The role and mechanism of TSC in kidney diseases: a literature review.

Qiulin Luo, Xinguo Zheng, Ye Xu, Yuxi Fan, Hedong Zhang, Tengfang Li, Xiangqi Zhang, Longkai Peng, Xin Jiang, Helong Dai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiulin Luo *Department of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, China.
Xinguo Zheng *Department of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, China.
Ye XuMedical College of Guangxi University, Nanning, 530004, China.
Yuxi FanDepartment of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, China.
Hedong ZhangDepartment of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Tengfang LiDepartment of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Xiangqi ZhangDepartment of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, 410013, China.
Longkai PengDepartment of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Xin JiangDepartment of Organ Transplantation, The Fifth Clinical Medical College of Henan, University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, 450000, China.
Helong DaiDepartment of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China. helong68888@163.com.

Funding

National Natural Science Foundation of China 82270796, 82070776,82200849 and 82370761Natural Science Foundation of Hunan Province 2023JJ40872Science and Technology Program of Hunan Province 2022RC3071
6 · The paper itself

Abstract

backgroundTuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by multisystem involvement, primarily caused by loss-of-function mutations in the TSC1 or TSC2 genes. TSC is a key integrator of metabolic signaling and cellular stress and has become an important regulator in several kidney diseases. TSC1 and TSC2 can be used not only as genetic markers for disease diagnosis, but also as potential immunotherapeutic targets for kidney disease. Recent studies on the pathogenesis of TSC may provide guidance for developing new treatment strategies for kidney diseases. KEY MESSAGES: Therefore, we systematically reviewed the molecular biology of TSC and their signaling pathway, regulation of cell metabolism, and immune response in acute renal injury, chronic kidney disease, diabetic kidney disease, renal cysts, benign and malignant intrarenal tumors, and renal angiomyolipomas. We also summarize the efficacy and adverse effects of mTOR inhibitors in the treatment of TSC-related kidney diseases.

Indexed as

Kidney DiseasesTuberous SclerosisHumansKidney NeoplasmsSignal TransductionTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTSC1 protein, humanTSC2 protein, humanTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinImmunotherapeuticKidney diseasesmTOR inhibitorsTuberous sclerosis complex

Identifiers

PMID40597820
PMCPMC12210502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.